Efficacy News and Research

RSS
John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Scancell's ImmunoBody vaccine technologies to be combined with ImmuneRegen's Homspera

Scancell's ImmunoBody vaccine technologies to be combined with ImmuneRegen's Homspera

Merck launches Oncology Collaborative Trials Network

Merck launches Oncology Collaborative Trials Network

Hiru, MindUp BioResearch comment on recent research findings in cancer treatments

Hiru, MindUp BioResearch comment on recent research findings in cancer treatments

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome

Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome

Amorfix Life Sciences signs licensing agreement with PREVENT

Amorfix Life Sciences signs licensing agreement with PREVENT

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

Study provides personalized strategies to boost AIAA compliance in breast cancer patients

Study provides personalized strategies to boost AIAA compliance in breast cancer patients

Medtronic DBS Therapy improves motor function in patients with advanced Parkinson's disease: Study

Medtronic DBS Therapy improves motor function in patients with advanced Parkinson's disease: Study

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.